Jim graduated in Biochemistry from the University of Strathclyde and obtained a PhD in drug metabolism from the University of Glasgow. He has over 30 years’ experience in the pharmaceutical and biotechnology industries, in Clinical Pharmacology & DMPK, working in France and the UK. Prior to joining Karus as a consultant in 2015, he had worked for Sanofi Aventis, GSK, Pfizer, J&J, Daichii Sankyo and Prosidion. At Sanofi Aventis, he was actively involved in the development team that gained approval for Pefloxacin®, whilst at Marion Merrell Dow (now Sanofi Aventis) he was involved in the early development of Dolasetron (Anzemet®), which was subsequently approved. He has worked with Karus on the successful delivery of INDs for the company’s two clinical agents. He has published over 40 scientific papers and co-authored 3 book chapters.